- cafead   Sep 16, 2024 at 10:12: AM
via Bristol Myers Squibb has jettisoned another cancer candidate in-licensed under its former CEO. Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific molecule that BMS picked up for $150 million upfront late in 2021.
article source
article source